Ansa Biotechnologies raised $71.5 million in an oversubscribed Series C round. Blue Water Life Science Advisors led the financing. The Emeryville, California company produces long, complex synthetic DNA for researchers.
Investor lineup
The round included new investors Illumina Ventures, BEVC, Lightscape Partners, and Agent Capital. Existing investors Cerberus Ventures, Fall Line Capital, Dauntless Ventures, and Altitude Life Science Ventures also participated. The financing brings Ansa's total funding to $211 million.
New board members
Nick Naclerio of Illumina Ventures, Brad Crutchfield, and Nate Cornell joined the board of directors. Rowan Chapman joined as a board observer. Matthew McManus stepped down from the board.
What the company offers
Ansa's enzymatic platform makes DNA sequences that conventional methods struggle to produce. It offers sequence-perfect clonal DNA up to 50 kilobases and sequence-verified linear double-stranded DNA fragments. Its On-Time Guarantee makes an order free if the complete shipment misses the committed date.
Ansa quadrupled its manufacturing capacity in the past year. The company plans to use the new capital to expand capacity and serve more customers. Demand is growing from drug discovery, cell and gene therapies, vaccines, and agrigenomics.